Royalty Pharma plc (RPRX)

Market Cap	18.08B
Revenue (ttm)	2.26B
Net Income (ttm)	858.98M
Shares Out	576.45M
EPS (ttm)	1.91
PE Ratio	16.41
Forward PE	6.72
Dividend	$0.88 (2.81%)
Ex-Dividend Date	Feb 21, 2025

Volume	4,077,104
Open	31.74
Previous Close	31.65
Day's Range	31.00 - 31.80
52-Week Range	24.05 - 34.20
Beta	0.47
Analysts	Strong Buy
Price Target	41.60 (+32.61%)
Earnings Date	May 8, 2025

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.

Analyst Forecast

According to 5 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $41.6, which is an increase of 32.61% from the latest price.

Price Target

$41.6

(32.61% upside)

Analyst Consensus: Strong Buy